期刊文献+

延长奥沙利铂输注时间预防其外周神经毒性的临床研究 被引量:6

Clinical observation of extending the infusion time when using oxaliplatin to prevent oxaliplatin neurotoxicity
下载PDF
导出
摘要 目的:在胃肠道肿瘤患者应用奥沙利铂+亚叶酸钙+氟尿嘧啶(FOLFOX方案)化疗后,观察延长奥沙利铂输注时间对其外周神经毒性的预防作用。方法:98例肿瘤患者随机分为三组,A组在使用奥沙利铂时将滴注时间延长至6小时;B组延长至4小时;C组奥沙利铂滴注时间为2小时。在化疗6周期及化疗12周期后分别比较三组神经毒性的总发生率及外周神经毒性级别。结果:6周期化疗后A组神经毒性的总发生率明显低于C组(P=0.0003);B组神经毒性的总发生率亦低于C组(P=0.034);A组神经毒性发生率低于B组(P=0.027),均具有统计学意义。12周期化疗后A组神经毒性的总发生率明显低于C组(P=0.002);B组神经毒性的总发生率亦低于C组(P=0.025);而A组和B组之间比较无统计学差异(P=0.371)。结论:使用奥沙利铂时将滴注时间延长至4-6小时可以有效减少神经毒性发生。 Objective:To evaluate the preventive effect to oxaliplatin neurotoxicity by extending the infusion time of using oxaliplatin in patients with gastrointestinal tumor after chemotherapy with FOLFOX regimen. Methods:All 98 cancer patients were randomized into three groups. Infusion time of group A was extended to 6 hours when using oxali-platin,Infusion time of group B and group C was 4 hours and 2 hours when using oxaliplatin. Then evaluated the inci-dence and level of oxaliplatin neurotoxicity after 6 cycles and 12 cycles of chemotherapy. Results:After 6 cycles of chemotherapy,the incidence of oxaliplatin neurotoxicity of group A was lower than that of group C(P=0. 0003),the incidence of group B was lower than that of group C as well(P=0. 034),and the incidence of group A was lower than that of group B(P=0. 027). After 12 cycles of chemotherapy,the incidence of group A was lower than that of group C(P=0. 002),the incidence of group B was lower than that of group C as well(P=0. 025),and the inci-dence had no statistical singnificance between the group A and B(P=0. 371). Conclusion:Extending the infusion time to 4-6 hours when using oxaliplatin can reduce the incidence of oxaliplatin neurotoxicity.
出处 《现代肿瘤医学》 CAS 2014年第10期2431-2433,共3页 Journal of Modern Oncology
关键词 奥沙利铂 神经毒性 预防 oxaliplatin neurotoxicity prevention
  • 相关文献

参考文献13

  • 1孙燕主编..内科肿瘤学[M].北京:人民卫生出版社,2001:1016.
  • 2吴敏华,陈旭烽,周月芬,应筱莉,王永辉.益气活血法与健脾补肾法预防奥沙利铂相关神经毒性[J].中华中医药学刊,2012,30(1):111-113. 被引量:23
  • 3Levi F,Misset JL,Brienza S,et al. A chronopharmacologic phase IIclinical trial with 5 - fluorouracil,folinic acid,and oxaliplatin usingan ambulatory multichannel programmable pump. High antitumoreffectiveness against metastatic colorectal cancer [ J ]. Cancer,1992,69(4) :893. 被引量:1
  • 4de Gramont A,Figer A,Seymour M,et al. Leucovorin and fluoroura-cil with or without oxaliplatin as first - line treatment in advancedcolorectal cancer[ J]. J Clin Oncol,2000,18( 16) :2938 -2947. 被引量:1
  • 5Extra JM,Espie M,Calvo F,et al. Phase I study of oxaliplatin inpatients with advanced cancer[ J]. Cancer Chemother Pharmacol,1990,25(4):299 -303. 被引量:1
  • 6Extra JM, Marty M, Brienza S, et al. Pharmacokinetics and safetyprofile of oxaliplatin[ J]. Semin Oncol, 1998,25(2 Suppl 5) :13 -22. 被引量:1
  • 7Andre T,Bensmaine MA,Louvet C,et al. Multicenter phase II stud-y of bimonthly high - dose leucovorin, fluorouracil infusion,and ox-aliplatin for metastatic colorectal cancer resistant to the same leuco-vorin and fluorouracil regimen [ J]. J Clin Oncol,1999,17 ( 11 ):3560 -3568. 被引量:1
  • 8Misset JL,Brienza S,Taamma A. Pharmacokinetics,urinary and fe-cal excretion of oxaliplatin in cancer patients[ J] . Am Ass CancerRes Meeting Abstract, 1996,5 (37) ; 1252 - 1255. 被引量:1
  • 9Gamelin E, Bouil AL,Boisdron - Celle M,et al. Cumulative phar-macokinetic study of oxaliplatin,administered every three weeks,combined with 5 - fluorouracil in colorectal cancer patients [ J].Clin Cancer Res,1997,3(6) :891 -899. 被引量:1
  • 10ArmandJP,孙燕,管忠震,鞠利雅.草酸铂 (奥沙利铂 )治疗大肠癌的研究进展[J].癌症,1999,18(6):624-630. 被引量:88

二级参考文献31

  • 1弓晓霞.补阳还五汤预防奥沙利铂外周神经毒性的临床观察[J].河南中医,2005,25(11):68-68. 被引量:24
  • 2徐建明.大肠癌内科治疗现状的认识和评价[J].中华肿瘤杂志,2005,27(12):705-707. 被引量:13
  • 3Giacchetti S,Perpoint B,Zidan IR,et al.Phase Ⅲ multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovor in as first-line treatment of metastatic colorectal cancer[J].Clin Oncol,2000,18(3):136-147. 被引量:1
  • 4Grothey A,Deschler B,K roening H,et al.Phase Ⅲ study of bolus 5-fluorouracil (5-Fu)/folinic acid (FA)(Mayo)vs weekly high-dose 24h 5-FU infusion/ FA +oxa lipla tin(OXA)(FUFOX)in advanced colorectal cancer(ACRC) (abstract 512)[J].Proc Am Soc Clin Oncol,2002,21(10):129. 被引量:1
  • 5Kelly H,Goldberg RM.Systemic therapy for metastatic colorectal cancer:currentoptions,current evidence[J].Clinoncol,2005,23(1):4553-4560. 被引量:1
  • 6Aggarwal S,Chu E.Current therapies for advanced colorectal cancer[J].Oncology(WiIIiston Park),2005,19(1):589-595. 被引量:1
  • 7BecouarnY,AgostiniC,TrufflandierN,eta1.Oxaliplatin:Availabledatainnon-colorectal gastrointestinal malignancies[J].Crit Rev Oncol Hematol,2001,40(3):265-272. 被引量:1
  • 8Cassidy J,Misset JL.OxaIiplatin-related side effects:Characteristics and management[J].Semin Oncol,2002,29(5):11-20. 被引量:1
  • 9Holmes J,Stanko J,Varchenko M,et al.Comparative neurotoxicity of oxaliplatin,cisplatin and ormaplatin in a wistar rat model[J].Toxicol Sci,1998,46(2):342-351. 被引量:1
  • 10Gmnelin E,Gamelin L,Bossi L,et al.Clinical aspects and molecular basis of oxaliplatin neurotoxicity:current management and development of preventive measures[J].Semin Oncol,2002,29(1):21-33. 被引量:1

共引文献179

同被引文献70

引证文献6

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部